1. Scrip
  2. >>New Products

Stada Poised To Launch As Calliditas Finally Wins EU Nod For Kinpeygo

Stada To Commercialize In EU

 
• By Ayisha Sharma

The Swedish biotech’s patience paid off as it received a positive EU CHMP opinion on its rare nephrology drug Kinpeygo, known elsewhere as Tarpeyo, following delays related to manufacturing questions.  

Tarpeyo Now Has Two Major Regulatory Thumbs Ups • Source: Shutterstock

STADA Arzneimittel AG is getting ready to commercialize Calliditas Therapeutics AB’ nephrology product, Tarpeyo, now that it has received a positive opinion from the EU’s Committee for Medicinal Products for Human Use (CHMP) for it after an initial pushback from the body.

The CHMP issued a positive opinion on the EU approval of Tarpeyo (delayed-release budesonide) in immunoglobulin A nephropathy (IgAN) patients at risk of rapid disease progression with a urine protein-to-creatinine ratio of at least 1.5g/gram. The European Commission (EC) should confirm the decision by the third quarter, making Tarpeyo the first and only approved drug for IgAN on both sides of the Atlantic

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.